◀ Back to INS

DPH2 — INS

Text-mined interactions from Literome

Nabe et al., Endocrinology 2006 : Diphenylhydantoin ( DPH ) , which is clinically used in the treatment of epilepsy, inhibits glucose induced insulin release from pancreatic islets by a mechanism that remains unknown ... DPH also suppressed insulin release in the presence of 16.7 mm glucose, 200 microm diazoxide, and 30 mm K+ without affecting the intracellular Ca2+ concentration ... Taken together, DPH inhibits glucose induced insulin secretion not only by inhibiting mitochondrial ATP production, but also by reducing Ca2+ efficacy in the exocytotic system through its alkalizing effect on cytoplasm
Boquist et al., Eur J Pharmacol 1980 (Hyperglycemia) : Isolated mouse islets exposed to 3mM glucose released an increased amount of insulin in the presence of acetazolamide ( AZM ) ( 10 mM ) and diphenylhydantoin ( DPH ) ( 0.35 or 3.5 mM ), whereas insulin secretion due to 20 mM glucose was decreased in the presence of AZM ( 10 mM ) and DPH ( 0.35, 0.70 or 3.5 mM )